This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adams, J. M. Articles by Hall, J. E. Search for Related Content PubMed PubMed Citation Articles by Adams, J. M. Articles by Hall, J. E.

Polycystic Ovarian Morphology with Regular Ovulatory Cycles: Insights into the Pathophysiology of Polycystic Ovarian Syndrome

Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Dr. Janet E. Hall, Reproductive Endocrine Unit, BHX-5, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114. E-mail: jehall{at}partners.org.

To determine the relevance of polycystic ovarian morphology (PCOM) to the pathophysiology of polycystic ovarian syndrome (PCOS), biochemical features associated with PCOS were examined in 68 women with an established history of regular ovulatory cycles and no clinical evidence of hyperandrogenism. Ovarian morphology was objectively assessed by pelvic ultrasound. LH, FSH, estradiol (E₂), testosterone (T), androstenedione (₄A), SHBG, and dehydroepiandrosterone sulfate (DHEAS) were measured at baseline in the early follicular phase (EFP) in all subjects. LH, FSH, E₂, and progesterone (P₄) were then measured daily for a complete menstrual cycle in 16 women with normal ovarian morphology and in 26 women with PCOM. T, ₄A, SHBG, and DHEAS levels were measured in pools of three daily samples in each of the EFP, midcycle, and midluteal phases. An additional 26 normal women (13 with normal ovarian morphology and 13 with PCOM) were studied in the EFP to assess pulsatile LH secretion, insulin and glucose levels, and the ovarian response to human chorionic gonadotropin. At baseline, there were no differences in body mass index or hirsutism scores between women with PCOM and normal ovaries. In daily samples across the menstrual cycle LH, FSH, E₂, and P₄ did not differ between women with PCOM and those with normal ovaries, and there was no difference in LH pulse amplitude or frequency in the EFP frequent sampling studies. In women with PCOM, T (P < 0.01), free T (P < 0.005), and DHEAS (P < 0.01) levels were higher at baseline in the EFP, and SHBG was lower (P < 0.05). Differences in ₄A did not reach significance (P = 0.14). T, free T, ₄A, and DHEAS were also increased in PCOM across the menstrual cycle (P < 0.05). In addition, 17-hydroxyprogesterone (P < 0.02), ₄A (P < 0.01), and T (P < 0.01) responses to human chorionic gonadotropin were greater in women with PCOM. Fasting glucose was not different between the two groups, but fasting insulin was higher (P < 0.02) in PCOM women as was insulin resistance calculated from homeostatic model assessment (P < 0.01). These studies demonstrate that PCOM in nonhirsute women with documented ovulatory cycles is associated with normal E₂, P₄, and gonadotropin dynamics, but higher androgen and insulin levels and lower SHBG levels. Taken together, these findings suggest that PCOM with ovulatory cycles exists as a discrete entity, represents the mildest form of ovarian hyperandrogenism, and is associated with greater insulin resistance than in women with normal ovarian morphology. The absence of any neuroendocrine abnormality in women with PCOM and ovulatory cycles suggests that gonadotropin dysfunction is not required for increased androgen secretion, but may be critical for development of the anovulatory disorder associated with PCOS.

This article has been cited by other articles:

				T. M. Barber, S. J. Golding, C. Alvey, J. A. H. Wass, F. Karpe, S. Franks, and M. I. McCarthy Global Adiposity Rather Than Abnormal Regional Fat Distribution Characterizes Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 999 - 1004. [Abstract] [Full Text] [PDF]

				J. K Devin, J. E Johnson, M. Eren, L. A Gleaves, W. S Bradham, J. R Bloodworth Jr, and D. E Vaughan Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice J. Mol. Endocrinol., July 1, 2007; 39(1): 9 - 16. [Abstract] [Full Text] [PDF]

				C. K. Welt, J. A. Gudmundsson, G. Arason, J. Adams, H. Palsdottir, G. Gudlaugsdottir, G. Ingadottir, and W. F. Crowley Characterizing Discrete Subsets of Polycystic Ovary Syndrome as Defined by the Rotterdam Criteria: The Impact of Weight on Phenotype and Metabolic Features J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4842 - 4848. [Abstract] [Full Text] [PDF]

				C. K. Welt, G. Arason, J. A. Gudmundsson, J. Adams, H. Palsdottir, G. Gudlaugsdottir, G. Ingadottir, and W. F. Crowley Defining Constant Versus Variable Phenotypic Features of Women with Polycystic Ovary Syndrome Using Different Ethnic Groups and Populations J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4361 - 4368. [Abstract] [Full Text] [PDF]

				D. Dewailly, S. Catteau-Jonard, A.-C. Reyss, M. Leroy, and P. Pigny Oligoanovulation with Polycystic Ovaries But Not Overt Hyperandrogenism J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3922 - 3927. [Abstract] [Full Text] [PDF]

				M. K. Murphy, J. E. Hall, J. M. Adams, H. Lee, and C. K. Welt Polycystic Ovarian Morphology in Normal Women Does Not Predict the Development of Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3878 - 3884. [Abstract] [Full Text] [PDF]

				M. Mortensen, R. L. Rosenfield, and E. Littlejohn Functional Significance of Polycystic-Size Ovaries in Healthy Adolescents J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3786 - 3790. [Abstract] [Full Text] [PDF]

				C.K. Welt, Y. Jimenez, P.M. Sluss, P.C. Smith, and J.E. Hall Control of estradiol secretion in reproductive ageing Hum. Reprod., August 1, 2006; 21(8): 2189 - 2193. [Abstract] [Full Text] [PDF]

				S.K. Blank, C.R. McCartney, and J.C. Marshall The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2006; 12(4): 351 - 361. [Abstract] [Full Text] [PDF]

				E. Codner, N. Soto, P. Lopez, L. Trejo, A. Avila, F. C. Eyzaguirre, G. Iniguez, and F. Cassorla Diagnostic Criteria for Polycystic Ovary Syndrome and Ovarian Morphology in Women with Type 1 Diabetes Mellitus J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2250 - 2256. [Abstract] [Full Text] [PDF]

				Y. L. Pagan, S. S. Srouji, Y. Jimenez, A. Emerson, S. Gill, and J. E. Hall Inverse Relationship between Luteinizing Hormone and Body Mass Index in Polycystic Ovarian Syndrome: Investigation of Hypothalamic and Pituitary Contributions J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1309 - 1316. [Abstract] [Full Text] [PDF]

				N. I. Leibel, E. E. Baumann, M. Kocherginsky, and R. L. Rosenfield Relationship of Adolescent Polycystic Ovary Syndrome to Parental Metabolic Syndrome J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1275 - 1283. [Abstract] [Full Text] [PDF]

				R. Azziz Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 781 - 785. [Abstract] [Full Text] [PDF]

				C. K. Welt, A. E. Taylor, J. Fox, G. M. Messerlian, J. M. Adams, and A. L. Schneyer Follicular Arrest in Polycystic Ovary Syndrome Is Associated with Deficient Inhibin A and B Biosynthesis J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5582 - 5587. [Abstract] [Full Text] [PDF]

				S. Johnsen, S. E. Dolan, K. V. Fitch, K. M. Killilea, J. L. Shifren, and S. K. Grinspoon Absence of Polycystic Ovary Syndrome Features in Human Immunodeficiency Virus-Infected Women Despite Significant Hyperinsulinemia and Truncal Adiposity J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5596 - 5604. [Abstract] [Full Text] [PDF]

				S. A.R. Doi, M. Al-Zaid, P. A. Towers, C. J. Scott, and K. A.S. Al-Shoumer Irregular cycles and steroid hormones in polycystic ovary syndrome Hum. Reprod., September 1, 2005; 20(9): 2402 - 2408. [Abstract] [Full Text] [PDF]

				D.H. Abbott, D.K. Barnett, C.M. Bruns, and D.A. Dumesic Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum. Reprod. Update, July 1, 2005; 11(4): 357 - 374. [Abstract] [Full Text] [PDF]

				C. K. Welt, A. Falorni, A. E. Taylor, K. A. Martin, and J. E. Hall Selective Theca Cell Dysfunction in Autoimmune Oophoritis Results in Multifollicular Development, Decreased Estradiol, and Elevated Inhibin B Levels J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3069 - 3076. [Abstract] [Full Text] [PDF]

				R. S. Legro, P. Chiu, A. R. Kunselman, C. M. Bentley, W. C. Dodson, and A. Dunaif Polycystic Ovaries Are Common in Women with Hyperandrogenic Chronic Anovulation but Do Not Predict Metabolic or Reproductive Phenotype J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2571 - 2579. [Abstract] [Full Text] [PDF]